US 11,939,318 B2
LPA receptor antagonists and uses thereof
Brian P. Bestvater, Vancouver (CA); Joshua A. Kaplan, Acton, MA (US); Barton W. Phillips, San Mateo, CA (US); Kin S. Yang, Foster City, CA (US); and Anna Zagorska, Foster City, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Dec. 6, 2022, as Appl. No. 18/062,363.
Claims priority of provisional application 63/287,252, filed on Dec. 8, 2021.
Prior Publication US 2023/0212150 A1, Jul. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); C07D 401/04 (2006.01); C07D 413/14 (2006.01)
CPC C07D 401/14 (2013.01) [C07D 401/04 (2013.01); C07D 413/14 (2013.01)] 20 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.